预约演示
更新于：2026-09-29
Tranexamic Acid
氨甲环酸
更新于：2026-09-29
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C8H15NO2 |
InChIKeyGYDJEQRTZSCIOI-LJGSYFOKSA-N |
CAS号1197-18-8 |
关联
1,637
项与 氨甲环酸 相关的临床试验IRCT20190525043701N1
The effect of oral Tranexamic Acid for bleeding in Spinal Surgery
NCT07825350
Efficacy of Tranexamic Acid in the Reduction of Postoperative Complications Following Medial Opening Wedge High Tibial Osteotomy
NCT07828262
The Use of Tranexamic Acid in Decreasing Wound Complication in Total Ankle Replacement. A Pilot Randomized Controlled Trial
100 项与 氨甲环酸 相关的临床结果
登录后查看更多信息
100 项与 氨甲环酸 相关的转化医学
登录后查看更多信息
100 项与 氨甲环酸 相关的专利（医药）
登录后查看更多信息
8,060
项与 氨甲环酸 相关的文献（医药）2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Clinical outcomes of intense pulsed light combined with non-crosslinked sodium hyaluronate, tranexamic acid, and vitamin C mesotherapy for facial photoaging: a retrospective study
Article
作者: Li, Fei ; Xu, Jialu ; Wu, Yutong ; Wu, Xixin ; Qiu, Houhuang ; Wang, Fangfang ; Xu, Tianhua ; Chen, Xi ; Zhong, Ping ; Lin, Qiusheng
BACKGROUND:
Facial photoaging involves structural and functional deterioration across multiple skin layers. Single-modality treatments rarely address pigmentary, vascular, and dermal matrix changes concurrently. Intense pulsed light (IPL) is widely used for the treatment of dyschromia and vascular lesions. Mesotherapy incorporating non-crosslinked sodium hyaluronate (NCSH), tranexamic acid (TXA), and vitamin C (VC) has been introduced to improve skin hydration and related dermal parameters. The present study assessed the efficacy and safety of combining these modalities for facial rejuvenation.
METHODS:
Eighty-four patients underwent three sessions of IPL with mesotherapy. Standardized VISIA imaging was conducted before each treatment (T0, T1, T2) and at 1-2 months (T3) and 3-6 months (T4) post-treatment. Efficacy was assessed using the Modified Fitzpatrick Wrinkle Scale (MFWS) and Global Aesthetic Improvement Scale (GAIS); adverse events and satisfaction were recorded.
RESULTS:
All six VISIA parameters and MFWS scores improved significantly (p __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__<
CONCLUSIONS:
IPL combined with NCSH/TXA/VC mesotherapy provided safe, effective, and well-tolerated improvement in facial photoaging, representing a promising multimodal rejuvenation approach.
2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Exploring the mechanism of differential responses to combination therapy in melasma: pigmentary versus mixed pigmentary–vascular types—a clinical study based on interaction analysis
Article
作者: He, Yajie ; Chen, Dong ; Li, Xiaoyan ; Sun, Bo ; Guo, Wei ; Zhang, Xiaotian ; Nie, Lei ; Zhang, Yinping ; Li, Chen
BACKGROUND:
Melasma shows clinical heterogeneity, but the role of vascular components in treatment resistance remains unclear.
METHODS:
This retrospective cohort study included 75 melasma patients stratified by severity (mild/moderate/severe, n = 25 each) and classified into pure pigmentary (M-type, n = 42) and mixed pigmentary-vascular (M + V-type, n = 33). All received low-fluence Q-switched 1064 nm laser plus oral tranexamic acid. Primary outcome was modified Melasma Area and Severity Index (mMASI) reduction. Multiple regression and interactionanalyses were performed.
RESULTS:
M-type showed significantly higher mMASI reduction than M + V-type (p < 0.001). Treatment resistance rate was markedly higher in M + V-type (p < 0.001). M + V-type, diseaseduration ≥5 years, and severe disease were independent negative predictors. A significantclinical type × severity interaction was detected (p = 0.018), with the M + V effect most pronounced in severe patients.
CONCLUSION:
Mixed pigmentary-vascular type is independently associated with poor response, aggravated by severe disease. For severe M + V-type, adjunctive anti-vascular or anti-inflammatory strategies may be warranted.
2026-12-31ANNALS OF MEDICINE
Tranexamic acid in spontaneous intracerebral hemorrhage: an updated systematic review and meta-analysis of randomized controlled trials
Review
作者: Liu, Zhenhong ; Que, Cuilin ; Lai, Xinxing ; Gao, Ying ; Feng, Luda ; Zhang, Hongrui ; Kong, Lingbo ; Gao, Yonghong ; Tao, Chenxi
BACKGROUND:
Tranexamic acid (TXA) is a well-established antifibrinolytic medication in the general population. However, its efficacy and safety for patients with spontaneous intracerebral hemorrhage (ICH) remain inconclusive. Consequently, we conducted a systematic review and meta-analysis to assess the effectiveness and safety of TXA for spontaneous ICH.
METHODS:
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) following established methodological standards. Our search encompassed eight electronic databases from inception to April 25, 2024. The primary outcome was a reduction in all-cause mortality. The secondary outcomes included improvements in functional independence, neurological impairment, activities of daily living, and reduction in hematoma expansion (HE). Fixed-effects or random-effects model were performed for pooled data where eligible.
RESULTS:
A total of 9 RCTs that initially enrolled 3,124 patients were included. There were no significant differences observed concerning all-cause mortality (RR, 1.03; 95% CI [0.89-1.18]), hematoma expansion (RR, 0.90; 95% CI [0.80-1.00]), improvement of functional independence (RR, 1.02; 95% CI [0.92-1.12], neurological impairment (MD, -0.88 [95% CI, -2.22-0.45]), or activities in daily living (MD, -0.83 [95% CI, -29.25-12.59]). The pooled data indicated that TXA for ICH was associated with a decrease in hematoma volume from baseline (MD, -1.74; 95% CI [-2.47 to -1.02]). No significant difference in adverse events was observed between the TXA group and the control group.
CONCLUSIONS:
In summary, TXA does not affect all-cause mortality, functional outcomes, or neurological impairment, nor does it reduce HE, despite reducing hematoma volulume. TXA use for ICH requires careful clinical consideration.
100 项与 氨甲环酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 凝血障碍 | 澳大利亚 | 1991-09-05 | |
| 遗传性血管性水肿 | 澳大利亚 | 1991-09-05 | |
| 前房出血 | 澳大利亚 | 1991-09-05 | |
| 月经过多 | 澳大利亚 | 1991-09-05 | |
| 血友病 | 美国 | 1986-12-30 | |
| 血友病 | 美国 | 1986-12-30 | |
| 红斑 | 日本 | 1969-01-16 | |
| 瘙痒 | 日本 | 1969-01-16 | |
| 肿胀 | 日本 | 1969-01-16 | |
| 药物性皮炎 | 日本 | 1965-08-31 | |
| 出血 | 日本 | 1965-08-31 | |
| 咽喉炎 | 日本 | 1965-08-31 | |
| 口腔炎 | 日本 | 1965-08-31 | |
| 扁桃体炎 | 日本 | 1965-08-31 | |
| 荨麻疹 | 日本 | 1965-08-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 口腔出血 | 临床3期 | 美国 | 2023-11-07 | |
| 口腔出血 | 临床3期 | 克罗地亚 | 2023-11-07 | |
| 口腔出血 | 临床3期 | 匈牙利 | 2023-11-07 | |
| 口腔出血 | 临床3期 | 罗马尼亚 | 2023-11-07 | |
| 口腔出血 | 临床3期 | 西班牙 | 2023-11-07 | |
| 肠道疾病 | 临床3期 | 中国 | 2023-03-27 | |
| 肠阻塞 | 临床3期 | 美国 | 2022-06-28 | |
| 胃肠功能紊乱 | 临床3期 | 中国 | 2022-01-30 | |
| 脑出血 | 临床3期 | 尼泊尔 | - | 2021-02-08 |
| 血肿 | 临床3期 | 尼泊尔 | - | 2021-02-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 7 | 鏇製膚廠衊遞鬱壓憲遞(廠繭憲獵膚繭網範鹹醖) = Bleeding severity showed no clear correlation with baseline FV or FVIII levels in agreement with prior international series 襯繭膚選壓選醖壓衊糧 (繭廠簾選壓網糧製齋齋 ) 更多 | 积极 | 2026-07-14 | |||
N/A | 15 | 鏇構鬱願窪繭夢範餘鑰(廠選積糧憲遞膚憲觸窪) = 醖餘淵壓鬱鹹夢選襯淵 鏇艱窪壓餘餘蓋壓鏇簾 (積願鏇鑰鹽餘壓觸顧夢 ) | 积极 | 2026-07-12 | |||
临床3期 | 283 | 餘築遞製膚鹽壓窪鏇窪(齋餘齋鹽鬱餘衊餘憲範): P-Value = 0.183 更多 | 不佳 | 2026-07-01 | |||
Placebo | |||||||
临床4期 | - | 8,273 | 網鹽網構選鬱鏇鏇簾網(膚鏇鹽觸築餘顧鹽獵築) = 糧窪鏇膚選構淵構顧網 壓餘憲淵鬱構網簾壓繭 (齋鏇醖夢襯觸願醖艱鏇 ) 更多 | 积极 | 2026-06-25 | ||
Placebo | 網鹽網構選鬱鏇鏇簾網(膚鏇鹽觸築餘顧鹽獵築) = 膚壓獵夢醖窪淵窪獵鹹 壓餘憲淵鬱構網簾壓繭 (齋鏇醖夢襯觸願醖艱鏇 ) 更多 | ||||||
临床4期 | 115 | Avoidance of Deliberate Hypotensive Anesthesia+TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION | 鹽餘製積廠淵簾鹹夢襯(築壓窪選繭醖齋積醖廠) = 衊製憲蓋顧鬱鏇鬱憲鏇 廠襯艱淵襯鑰觸築淵壓 (獵壓淵淵觸衊遞網餘鹹, 0.5) 更多 | - | 2026-05-27 | ||
N/A | 196 | 窪範製襯餘獵齋壓窪鬱(窪鏇齋網蓋廠鬱糧積遞): P-Value = 0.5601 更多 | 积极 | 2026-05-15 | |||
No Tranexamic acid | |||||||
临床3期 | 1,694 | Tranexamic acid + prophylactic oxytocin | 餘範蓋膚夢願簾積範鏇(衊簾鑰壓願製遞築憲鬱) = 觸醖鏇鏇鬱遞築窪憲壓 繭襯遞憲膚窪餘範淵鹽 (遞鹽範選艱範願獵壓積 ) 更多 | 积极 | 2026-05-13 | ||
Placebo + prophylactic oxytocin | 餘範蓋膚夢願簾積範鏇(衊簾鑰壓願製遞築憲鬱) = 鏇遞繭壓壓廠製遞選蓋 繭襯遞憲膚窪餘範淵鹽 (遞鹽範選艱範願獵壓積 ) 更多 | ||||||
N/A | 410 | 鹹鏇遞餘憲壓壓鏇鏇鑰(蓋築選膚顧願糧網膚顧) = 築鏇膚鬱鬱顧鏇夢顧醖 範膚簾糧願夢製淵醖齋 (簾憲糧淵選繭觸選鹽鹹 ) 更多 | 积极 | 2026-05-12 | |||
临床4期 | - | 43 | 膚鬱襯遞願簾蓋觸範鬱(製襯遞繭襯廠齋廠廠積) = 鹽顧願鑰蓋衊築築膚願 鏇襯網襯齋願網鏇觸遞 (糧醖繭製網積衊衊鬱觸 ) 更多 | 积极 | 2026-04-14 | ||
N/A | 48 | Placebo | 構壓願網窪醖窪鹹鹽繭 = 壓製網夢鹹獵鹽選衊鬱 願廠製築網獵獵鑰遞憲 (齋鬱憲構構鬱構鏇餘選, 衊夢蓋顧醖觸鹽夢艱獵 ~ 範築鏇鹽鹽鏇選鹹襯壓) 更多 | - | 2026-03-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用